Tech Company Inital Public Offerings
G1 Therapeutics IPO
Operating out of Research Triangle Park, G1 Therapeutics is now a public company.
Transaction Overview
Company Name
Announced On
5/17/2017
Transaction Type
IPO
Amount
$105,000,000
Proceeds Purpose
We intend to use the net proceeds from this offering as follows: approximately $45 million to advance development of trilaciclib; approximately $20 million to advance development of G1T38; approximately $15 million for drug manufacturing and to advance development of G1T48; and the balance for working capital and general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
700 Park Offices Dr. 200
Research Triangle Park, NC 27709
USA
Research Triangle Park, NC 27709
USA
Phone
Website
Email Address
Overview
G1 Therapeutics (Nasdaq: GTHX) is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology. The company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of first-in-class compounds and best-in-class drug candidates.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark Velleca
Chief Medical Officer
Raj Malik
Chief Scientific Officer
Jay Strum
VP - Bus. Development
Mark Avagliano
VP - Bus. Development
John Demaree
VP - Operations
Terry Murdock
Browse more venture capital transactions:
Prev: 5/17/2017: OpenMethods venture capital transaction
Next: 5/17/2017: Aira venture capital transaction
Share this article
News on VC Transactions
We do our best to report on tech company VC transactions. All VC database entries on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs